Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002766 · ClinicalTrials.gov registry record · Phase 3
Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma
A Phase 3 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 170
- Enrollment target
NCT00002766: Completed Phase 3 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00002766 is a Phase 3 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 170 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002766, a Phase 3 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 170 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is more effective for acute lymphoblastic leukemia, lymphoblastic lymphoma, or chronic myelogenous leukemia. PURPOSE: This randomized phase III trial is studying two different chemotherapy regimens and comparing them to see how well they work in treating adults with acute lymphoblastic leukemia, lymphoblastic lymphoma, or chronic myelogenous leukemia.
Interventions
- DRUG cyclophosphamide
- DRUG carmustine
- DRUG cytarabine
- BIOLOGICAL sargramostim
- BIOLOGICAL dactinomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 1996-03 |
| Est. Completion | 2011-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002766
The ClinicalTrials.gov registry entry for NCT00002766 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00002766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002766 about?
NCT00002766 is a clinical study titled "Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is more effective for acute lymphoblastic leukemia, lymphoblas...
What is the current status of trial NCT00002766?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 170 participants. The study started on 1996-03. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00002766?
The interventions under investigation include: cyclophosphamide (DRUG), carmustine (DRUG), cytarabine (DRUG), sargramostim (BIOLOGICAL), dactinomycin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002766?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.